Logo
x

Search

Subscribe Now

thyroid eye disease

Horizon Therapeutics' Tepezza (teprotumumab-trbw) Receives the US FDA's Approval as the First Therapy for Thyroid Eye Disease

Horizon Therapeutics' Tepezza (teprotumumab-trbw) Receives the US FDA's Approval as the First Therapy for Thyroid Eye Disease

  • January 22, 2020
Horizon Therapeutics Reports P-IV Clinical Trial Results of Tepezza (teprotumumab-trbw) for Chronic/Low Clinical Activity Score Thyroid Eye Disease

    Horizon Therapeutics Reports P-IV Clinical Trial Results of Tepezza (teprotumumab-trbw) for Chronic/Low Clinical Activity Score Th...

    • April 11, 2023
    Horizon Reports the Completion of Patients Enrollment of Tepezza (teprotumumab-trbw) in the P-III (OPTIC-J) Trial for the Treatment of Active Thyroid Eye Disease

      Horizon Reports the Completion of Patients Enrollment of Tepezza (teprotumumab-trbw) in the P-III (OPTIC-J) Trial for the Treatmen...

      • November 17, 2022
      Horizon Reports the Completion of Patient Enrollment of Tepezza (teprotumumab-trbw) in P-IV Trial for Thyroid Eye Disease

        Horizon Reports the Completion of Patient Enrollment of Tepezza (teprotumumab-trbw) in P-IV Trial for Thyroid Eye Disease

        • September 30, 2022
        Horizon Initiates P-III (OPTIC-J) Trial of Teprotumumab for the Treatment of Active Thyroid Eye Disease

          Horizon Initiates P-III (OPTIC-J) Trial of Teprotumumab for the Treatment of Active Thyroid Eye Disease

          • February 24, 2022
          Horizon Therapeutics

            Horizon Therapeutics' Tepezza (teprotumumab-trbw) Receives the US FDA's Approval as the First Therapy for Thyroid Eye Disease

            • January 22, 2020
            Image

            Incisive News in 3 Shots.

            Contact Us

            Our Information

            Follow Us

            Copyright © 2025 PharmaShots - All Rights Reserved.